Santhera Pharmaceuticals Holding AG (OTCMKTS:SPHDF – Get Free Report) dropped 7.5% during mid-day trading on Wednesday. The stock traded as low as $18.30 and last traded at $18.30. 110 shares traded hands during trading, a decline of 93% from the average session volume of 1,521 shares. The stock had previously closed at $19.79.
Santhera Pharmaceuticals Price Performance
The stock’s fifty day moving average is $21.94 and its 200 day moving average is $22.10.
About Santhera Pharmaceuticals
Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company focused on developing and commercializing treatments for rare neuromuscular diseases. Its research and development activities have centered on conditions with significant unmet medical needs, including Duchenne muscular dystrophy (DMD) and mitochondrial disorders.
The company’s lead product is vamorolone, marketed in the United States under the brand name Agamree. Vamorolone is a corticosteroid analogue developed to help treat DMD while potentially reducing some of the long-term side effects associated with conventional corticosteroid therapy.
See Also
- Five stocks we like better than Santhera Pharmaceuticals
- AST SpaceMobile’s BlueBird Progress Comes With Several Risks Still Unresolved
- Time to Nibble on MCD Stock After it Enters Oversold Territory?
- McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal Upside
- Corning and AT&T’s $3 Billion Fiber Deal Reveals Where AI Spending Goes Next
Receive News & Ratings for Santhera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Santhera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
